View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
February 11, 2022

CureVac doses first subject in Phase I influenza vaccine trial

Set to be carried out in Panama, the trial is anticipated to enrol up to 240 healthy subjects.

CureVac has dosed the first subject in a Phase I trial of its seasonal influenza second-generation messenger ribonucleic acid (mRNA) vaccine candidate, CVSQIV.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

The open-label, dose-escalation trial will analyse the safety, reactogenicity and immunogenicity of the vaccine in doses ranging from 3µg to 28µg.

Set to be carried out in Panama, it is anticipated to enrol up to 240 healthy subjects of the age groups of 18-55 years and 65 years and older.

The differentiated multivalent vaccine candidate was developed by CureVac in collaboration GlaxoSmithKline (GSK).

It merges several separate nonchemically modified constructs of mRNA encoding for antigens that address four varying influenza strains.

CureVac noted that the seasonal influenza vaccine candidate is the first in the clinical stage based on an advanced mRNA backbone of CureVac.

Furthermore, it is one among the second-generation mRNA vaccine candidates from the infectious disease programme developed through partnership between CureVac and GSK.

CureVac chief development officer Dr Klaus Edvardsen said: “The successful implementation of mRNA technology to address the global Covid-19 pandemic has demonstrated a tremendous opportunity for this platform.

“Leveraging the inherent flexibility of our mRNA platform together with our fast manufacturing, we have successfully combined multiple different mRNAs in a single candidate with the goal to develop a potentially improved vaccine for seasonal influenza.”

Apart from this vaccine, the companies are working on chemically modified mRNA technologies with clinical programmes for Covid-19 and influenza slated to commence this year.

In addition, a clinical trial to analyse usage of chemically modified mRNA is anticipated to start later this year.

In August last year, GSK and CureVac reported that their second-generation vaccine candidate, CV2CoV, offered strong immune responses against SARS-CoV-2 challenge in non-human primates in a preclinical study.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena